Trials built for the age of innovation
Personalized medicine offers tremendous hope for patients. This change in focus to specialty treatments for highly defined patient populations also requires a change in how research works, customized just as specifically as the treatments it is designed to test.
57 orphan drugs
Number of drugs with orphan indications approved in the U.S. between January and August 201815 oncology drugs
The number of new oncology therapeutics launched in 2018$452 billion
Projected value of the biologics market in 2022
Powering change with the IQVIA CORE
IQVIA combines deep therapeutic and scientific knowledge with unmatched experience in clinical trial design and execution. Using the IQVIA CORE we can integrate data, analytics, and technology around the specific requirements of your trial. So we can anticipated challenges, ask the right questions and help you
- Reach milestones faster:从识别可能成功的试验站点，到招募合适的患者
- 更精确：From choosing indications, to comparing scenarios and analyzing key metrics to drive better decisions
- Leverage the expertise you need:From artificial intelligence and machine learning, to experts in local markets around the world
使用先进的分析来评估您针对现实世界证据的协议，并降低昂贵修订的风险。
Leverage a global network of Phase I clinical pharmacology units to build diversity in patient populations and access a range of geographic regions for early clinical development (ECD) programs.
通过IQVIA核心的力量提高临床试验的性能。手机版必威
Identify the best performing sites for your trial in less time with new machine learning and predictive modeling methods.
使用数据驱动的患者招聘解决方案可以更准确地预测入学率，并增加每个部位的患者数量。
Access central labs around the globe through Q2 Solutions, a wholly owned subsidiary of IQVIA.
使用我们的全球功能资源和灵活的服务来降低临床开发成本并提高研究质量，并从您的研发支出中获得更多价值。
直接向患者带来试验，以改善访问和参与度，提高质量并缩短时间表。
Discover unrealized connections and manage your product across the entire lifecycle, from research and development, compliance to launch and commercialization.